The objective of our research was to examine the levels of circulating LOXL1-AS1 in EOC patients and to analyze its diagnostic and prognostic value.
The levels of LOXL1-AS1 in 185 EOC patients and 43 healthy volunteers were evaluated by Quantitative Real-time PCR (qRT-PCR). The potential of LOXL1-AS1 as a biomarker for EOC diagnosis was determined by ROC curve assays. The associations between clinicopathological parameters and LOXL1-AS1 expression were analyzed using chi-square test. The influence of LOXL1-AS1 on overall survival was analyzed by the use of Kaplan-Meier. A Cox proportional hazards assays were conducted for the determination of the prognostic value of LOXL1-AS1.
The expressions of LOXL1-AS1 were dramatically higher in EOC patients than those in healthy controls (p < 0.01). LOXL1-AS1 yielded an area under the ROC curve of 0.843 with 65.3 % sensitivity and 68.2 % specificity in discriminating high-grade EOC from healthy controls. It was also proved that LOXL1-AS1 expression was associated with advanced FIGO stage (p = 0.004) and positively distant metastasis (p = 0.013). Kaplan-Meier assays revealed that patients with high LOXL1-AS1 expressions had a shorter overall survival than those with low expressions (p = 0.0006). By performing multivariate assays, LOXL1-AS1 was confirmed to be an independent prognostic factor for predicting prognosis of EOC patients.
We provided evidence that LOXL1-AS1 expression is correlated with poor clinical outcome of EOC patients and may act as an independent prognostic indicator as well as a new diagnostic biomarker.

This article is protected by copyright. All rights reserved.